Current research is centered on augmenting the immune response provoked by RT, potentially through inhibiting the tumor-intrinsic E3 ligase tumor cell-intrinsic tripartite motif-containing 21 (TRIM21), to further bolster antitumor immunity [42]. The gene discussed is TRIM21; the disease is neoplasm.